Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microbicide research and development--where to?

R Rustomjee, Q Abdool Karim

    HIV Clinical Trials
    |October 9, 2001
    PubMed
    Summary
    This summary is machine-generated.

    Nonoxynol-9 (N-9) shows no efficacy against HIV and limited protection against STIs, with significant dose-related adverse effects. Research should focus on developing alternative microbicides for women

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003).

    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2018
    Same author

    The dual burden of gender-based violence and HIV in adolescent girls and young women in South Africa.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2016
    Same author

    Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.

    Mucosal immunology·2016
    Same author

    Understanding and responding to HIV risk in youngSouth African women: Clinical perspectives.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2016
    Same author

    Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.

    Mucosal immunology·2016
    Same author

    Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women.

    BMC infectious diseases·2016
    Same journal

    Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.

    HIV clinical trials·2019
    Same journal

    Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.

    HIV clinical trials·2019
    Same journal

    Participant characteristics and clinical trial decision-making factors in AIDS malignancy consortium treatment trials for HIV-infected persons with cancer (AMC #S006).

    HIV clinical trials·2019
    Same journal

    Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial.

    HIV clinical trials·2019
    Same journal

    Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.

    HIV clinical trials·2019
    Same journal

    Natural control of HIV infection in young women in South Africa: HPTN 068.

    HIV clinical trials·2018
    See all related articles

    Area of Science:

    • Reproductive Health
    • Infectious Disease Prevention
    • Microbicide Research

    Background:

    • Rising HIV infections in women necessitate women-initiated prevention methods.
    • An effective microbicide is crucial where existing strategies fail.
    • Nonoxynol-9 (N-9) has been evaluated for its anti-HIV and anti-STI activity.

    Discussion:

    • Clinical trials of N-9 demonstrate a lack of efficacy against HIV.
    • Evidence for N-9's protection against STIs is limited.
    • N-9 exhibits dose-related adverse effects, raising safety concerns.

    Key Insights:

    • N-9 is not an effective HIV prevention tool.
    • N-9 offers minimal protection against STIs and poses safety risks.
    • Alternative microbicide candidates require further development.

    Related Experiment Videos

    Outlook:

    • Focus should shift to advancing preclinical and clinical testing of novel microbicides.
    • Exploring diverse mechanisms of action is essential for future microbicide development.
    • Continued research is vital to provide women with effective HIV prevention options.